- Home
- » Tags
- » Emibetuzumab
Top View
- (INN) for Biological and Biotechnological Substances
- LY2875358), As Monotherapy and in Combination with Erlotinib in Advanced Cancer Lee S
- A Phase 1B/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
- MM-131, a Bispecific Anti-Met/Epcam Mab, Inhibits HGF-Dependent and HGF-Independent Met Signaling Through Concurrent Binding to Epcam
- Clinical Development of C-MET Inhibition in Hepatocellular Carcinoma
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of Emibetuzumab in Asian Patients with MET Diagnostic Positive, Advanced Gastric Cancer
- Targeting Rare Mutations in Advanced Non-Small Cell Lung Cancer
- MET Exon 14 Skipping Alterations in Non-Small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances
- (12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
- Systemic Treatment of Hepatocellular Carcinoma: from Sorafenib to Combination Therapies
- A Potential Mechanism of Tumor Progression During Systemic Infections Via the Hepatocyte Growth Factor (HGF)/C-Met Signaling Pathway
- PET Imaging of Receptor Tyrosine Kinases in Cancer Weijun Wei1,2,Dalongni2, Emily B
- A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
- Preclinical Evaluation of MCLA-129: a Bispecific Antibody Targeting C-MET and EGFR
- W J C O Clinical Oncology
- Breast Cancer Cancer Drug Pipeline Information for Patient Advocacy
- ( 12 ) Patent Application Publication
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer James J
- Advocating for Action in HCC
- Sym015: a Highly Efficacious Antibody Mixture Against MET-Amplified Tumors
- (INN) for Biological and Biotechnological Substances
- First-In-Human Phase I Study of BPI-9016M, a Dual MET/Axl Inhibitor, in Patients with Non-Small Cell Lung Cancer
- A Phase 1B/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
- A Highly Efficacious Antibody Mixture Against MET-Amplified Tumors
- Comprehensive Review of Targeted Therapy for Colorectal Cancer
- Cmet Axis in Cancer Therapy
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri